ModifiedmhnPolicy CP.PMN.192

Brimonidine tartrate (Mirvaso) topical gel for persistent facial erythema of rosacea

This policy governs medical necessity criteria, prior authorization, and coverage parameters for topical brimonidine (Mirvaso) for treating persistent facial erythema of rosacea in adults and applies to members under the payer's Commercial, HIM/ICHRA, and Medicaid lines of business.

Policy Summary

Payermhn

PolicyBrimonidine tartrate (Mirvaso) topical gel for persistent facial erythema of rosacea

Policy CodePolicy CP.PMN.192

Change TypeMaterial updates: step therapy bypass (IL HIM), standardized approval duration, dose restriction removed

Effective DateJun 1, 2019

Next Review Date

Key ActionSubmit prior authorization with documentation that member meets all approval criteria, including diagnosis of persistent facial erythema, age ≥18, and adherence to step therapy or applicable bypass.

SourceLink

POLICY UPDATE CHANGES

Added step therapy bypass for generic and brand Mirvaso requests for Illinois HIM per IL HB 5395.

Standardized approval duration language for Commercial to align with Medicaid/HIM and added ICHRA line of business.

Removed the 30 mg/month maximum dose restriction.

Added step therapy bypass for brand Mirvaso for Illinois HIM per IL HB 5395.

Standardized approval duration language for Commercial to align with Medicaid/HIM and added that plan-approved quantity limit may apply.

≥18minimum age for coverage

1 tube/monthmaximum covered dose

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

12 monthsapproval duration

Commercial,HIM/ICHRA,Medicaidlines of business

IL HB 5395legislation (IL)

Coverage Criteria

inv-01: Initial Therapy

Covered when ALL of the following are met:

Facial Erythema Associated with Rosacea (Initial): 1. Diagnosis of persistent facial erythema associated with rosacea; 2. Age ≥ 18 years; 3. For brand Mirvaso requests, member must use generic topical brimonidine unless contraindicated or clinically significant adverse effects are experienced; 4. If papules or pustules are present, failure of, or concomitant treatment with, topical metronidazole OR oral doxycycline OR ivermectin cream OR azelaic acid (Finacea), unless contraindicated or clinically significant adverse effects are experienced; 5. For Illinois HIM requests, the step therapy requirements above do not apply as of 1/1/2026 per IL HB 5395; 6. Request does not exceed health plan-approved quantity limit, if applicable; 7. Dose does not exceed 1 tube per month.

Approval duration: 12 months

inv-02: Continuation Therapy

Covered when ALL of the following are met:

Continuation Therapy: 1. Member meets one of the following: (a) currently receiving medication via Centene benefit or previously met initial approval criteria, OR (b) currently receiving medication and enrolled in a state/product with continuity of care regulations; 2. Member is responding positively to therapy; 3. For brand Mirvaso requests, member must use generic topical brimonidine unless contraindicated or clinically significant adverse effects are experienced; 4. Request does not exceed health plan-approved quantity limit, if applicable; 5. If request is for a dose increase, new dose does not exceed 1 tube per month.

Approval duration: 12 months

Non–FDA approved indications for topical brimonidine that are not specifically addressed in this clinical policy are not authorized for coverage unless the provider supplies sufficient documentation demonstrating efficacy and safety in accordance with the applicable off‑label use policies. Refer to CP.CPA.09 (Commercial), HIM.PA.154 (HIM/ICHRA), or CP.PMN.53 (Medicaid) as applicable when submitting off‑label requests.

When state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Providers should consult the applicable state Medicaid manual for any state‑specific coverage rules that supersede this policy.

Use of topical brimonidine for non‑FDA approved indications without meeting the requirements of the referenced off‑label use policies (CP.CPA.09 for Commercial, HIM.PA.154 for HIM/ICHRA, or CP.PMN.53 for Medicaid) is considered not authorized and will be treated as not medically necessary unless adequate supporting documentation is provided.

Coding and Product Availability

Product availability (NDC-like)NDC

NDC	Brimonidine tartrate gel 0.33% (30 gm tube or pump, 45 gm tube) - product availability

inv-07: Maximum monthly quantity

Maximum monthly quantity1 tube per month (one application/day)

Dosing frequencyApply a pea-size amount topically once daily to each of five facial areas (forehead, chin, nose, each cheek)

Approval duration noteRequests evaluated with an approval duration of 12 months

Provider Actions and Prior Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required. Requests must document that all approval criteria are met, including diagnosis of persistent facial erythema of rosacea and age ≥ 18 years. Approval duration: 12 months (standardized across Commercial, Medicaid, HIM, and ICHRA). Plan-approved quantity limits may apply and should be documented on the prior authorization or claim as applicable.

Approval duration: 12 months
Plan‑approved quantity limits may apply — document on PA/claim

Documentation Required

Required Documentation and Insufficient Documentation Risk

Provider must submit documentation (such as office chart notes, lab results, or other clinical information) supporting that the member has met all approval criteria. Requests lacking sufficient documentation to demonstrate the member meets all criteria (e.g., diagnosis of persistent facial erythema due to rosacea, age ≥ 18, required step therapy trials or exceptions) may be denied.

Background

Brimonidine tartrate topical gel is an alpha‑2 adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults ≥18 years. Its mechanism is thought to involve direct vasoconstriction of superficial facial blood vessels. When inflammatory lesions (papules/pustules) are present, therapies directed at those lesions (for example, topical metronidazole, oral doxycycline, ivermectin cream, or azelaic acid) are referenced as alternative or concurrent treatments in the clinical approach.

Definitions

inv-17: Persistent facial erythema

DefinitionPersistent (nontransient) facial erythema of rosacea

FDA indicationMirvaso indicated for topical treatment of persistent facial erythema in adults ≥18 years

Clinical contextTherapy aims to reduce erythema via direct vasoconstriction

inv-18: Anti-inflammatory doxycycline

DefinitionAnti-inflammatory dose doxycycline refers to doxycycline doses < 50 mg which exert anti-inflammatory effects without inducing antibiotic resistance.

MechanismExerts anti-inflammatory and biological activities relevant to rosacea rather than antibacterial selection pressure

Revision History

2019-06-01policy_effective

Policy effective date established for brimonidine tartrate topical gel (CP.PMN.192).

2025-04-24step_therapy_change

Added step therapy bypass for generic topical brimonidine for Illinois HIM per IL HB 5395; removed the 30 mg/month maximum dose restriction during 2Q 2025 review.

2025-07-15step_therapy_change

Added step therapy bypass for brand Mirvaso (in addition to generic brimonidine) for Illinois HIM per IL HB 5395.

Policy Summary

Payermhn

PolicyBrimonidine tartrate (Mirvaso) topical gel for persistent facial erythema of rosacea

Policy CodePolicy CP.PMN.192

Change TypeMaterial updates: step therapy bypass (IL HIM), standardized approval duration, dose restriction removed

Effective DateJun 1, 2019

Next Review Date

SourceLink

On This Page

Acceptable documentation: office notes, lab results, imaging, prior medication records

Step Therapy

Step Therapy / Generic‑First Requirement

Step therapy / generic‑first requirement: For brand Mirvaso requests, member must use generic topical brimonidine unless contraindicated or clinically significant adverse effects occur. If papules or pustules are present, there must be trial and failure of, or concomitant treatment with, topical metronidazole, oral doxycycline, ivermectin cream, or azelaic acid unless contraindicated or not tolerated.

Generic topical brimonidine required before brand Mirvaso unless contraindicated
If papules/pustules present: trial and failure or concomitant treatment with metronidazole, doxycycline, ivermectin cream, or azelaic acid

Step Therapy

IL HIM Step Therapy Bypass for Mirvaso

Step therapy bypass for Mirvaso (Illinois HIM): Per IL HB 5395, the step therapy requirements do not apply for Illinois HIM requests as of 1/1/2026. Additionally, a step therapy bypass was added for brand Mirvaso for Illinois HIM per IL HB 5395 — failure to follow this jurisdictional bypass requirement (when applicable) may result in denial for IL HIM members.

IL HIM step therapy bypass effective 01/01/2026 per IL HB 5395
Bypass applies to brand Mirvaso for IL HIM; ensure the bypass is applied for IL HIM claims/PA to avoid denial

Example product/dose

Oracea (doxycycline) 40 mg PO once daily for papules/pustules

inv-19: Health Plan

DefinitionHealth Plan: a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or affiliates.

Policy roleProvides guidance for medical necessity and coverage decisions; not a contract or guarantee of payment

ApplicabilityCoverage decisions subject to coverage documents, state/federal requirements, and Health Plan administrative policies

inv-20: Medicaid precedence

Medicaid precedenceFor Medicaid members, state Medicaid coverage provisions supersede this clinical policy when conflicts exist.

Action itemRefer to the applicable state Medicaid manual for specific coverage provisions

ScopePolicy language may be superseded by state Medicaid requirements even if included in this clinical policy

2025-06-12brand_redirection

Added redirection for brand Mirvaso requests to generic topical brimonidine.

2026-04-13approval_duration_and_lob_updateLatest

Standardized approval duration language for Commercial to align with Medicaid/HIM and added ICHRA line of business; clarified that plan-approved quantity limits may apply.